Literature DB >> 11801512

Adenovirus mediated gene delivery of tissue inhibitor of metalloproteinases-3 induces death in retinal pigment epithelial cells.

Mohammed A Majid1, Valerie A Smith, David L Easty, Andrew H Baker, Andrew C Newby.   

Abstract

BACKGROUND: Sorsby's fundus dystrophy (SFD) and age related macular degeneration (ARMD) are retinal diseases associated with a high level of accumulation of mutant and wild type TIMP-3, respectively, in Bruch's membrane. The pathogenic role of TIMP-3 in these diseases is uncertain, but causative mutations have been identified in the TIMP-3 gene of patients with SFD. Recent reports that TIMP-3 causes apoptosis in certain cell types and not in others prompted the authors to investigate whether TIMP-3 causes apoptosis in cultured retinal pigment epithelium (RPE) cells.
METHODS: RPE and MCF-7 cells (as a positive control) were initially infected with replication deficient adenovirus, to overexpress beta-galactosidase (RAdLacZ) or TIMP-3 (RAdTIMP-3). TIMP-3 was detected by western blotting and ELISA. Cell viability was defined by cell counts. ISEL was used to investigate the mechanism of cell death.
RESULTS: Cultured RPE cells produced small quantities of endogenous TIMP-3 and remained viable. However, overexpression of TIMP-3 caused a dose related death of RPE cells. The mechanism of cell death was apoptosis.
CONCLUSION: The previously unreported finding of TIMP-3 induced apoptosis of RPE cells may account for some of the early features seen in SFD and ARMD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801512      PMCID: PMC1770963          DOI: 10.1136/bjo.86.1.97

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  24 in total

1.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.

Authors:  A H Baker; A B Zaltsman; S J George; A C Newby
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

2.  Phenotypic heterogeneity of retinal pigment epithelial cells in vitro and in situ.

Authors:  J M Burke; C M Skumatz; P E Irving; B S McKay
Journal:  Exp Eye Res       Date:  1996-01       Impact factor: 3.467

3.  TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells.

Authors:  M R Smith; H Kung; S K Durum; N H Colburn; Y Sun
Journal:  Cytokine       Date:  1997-10       Impact factor: 3.861

4.  Sorsby's fundus dystrophy. A light and electron microscopic study.

Authors:  M R Capon; J Marshall; J I Krafft; R A Alexander; P S Hiscott; A C Bird
Journal:  Ophthalmology       Date:  1989-12       Impact factor: 12.079

5.  Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid.

Authors:  J A Vranka; E Johnson; X Zhu; A Shepardson; J P Alexander; J M Bradley; M K Wirtz; R G Weleber; M L Klein; T S Acott
Journal:  Curr Eye Res       Date:  1997-02       Impact factor: 2.424

6.  TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration.

Authors:  M Kamei; J G Hollyfield
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-09       Impact factor: 4.799

7.  Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye.

Authors:  R N Fariss; S S Apte; B R Olsen; K Iwata; A H Milam
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

8.  TIMP-3 is expressed in the human retinal pigment epithelium.

Authors:  A Ruiz; P Brett; D Bok
Journal:  Biochem Biophys Res Commun       Date:  1996-09-13       Impact factor: 3.575

9.  Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells.

Authors:  M Ahonen; A H Baker; V M Kähäri
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

10.  Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation.

Authors:  K P Langton; M D Barker; N McKie
Journal:  J Biol Chem       Date:  1998-07-03       Impact factor: 5.157

View more
  8 in total

Review 1.  Are fibroblasts involved in joint destruction?

Authors:  T Pap; I Meinecke; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

2.  Tissue inhibitor of metalloproteinase-3 differentially binds to components of Bruch's membrane.

Authors:  M A Majid; V A Smith; F J Matthews; A C Newby; A D Dick
Journal:  Br J Ophthalmol       Date:  2006-07-12       Impact factor: 4.638

3.  Matrix bound SFD mutant TIMP-3 is more stable than wild type TIMP-3.

Authors:  Mohammed A Majid; Valerie A Smith; Andrew C Newby; Andrew D Dick
Journal:  Br J Ophthalmol       Date:  2007-03-23       Impact factor: 4.638

4.  Tissue inhibitor of metalloproteinase-3 (TIMP3) promotes endothelial apoptosis via a caspase-independent mechanism.

Authors:  Jian Hua Qi; Bela Anand-Apte
Journal:  Apoptosis       Date:  2015-04       Impact factor: 4.677

Review 5.  Sorsby fundus dystrophy: Insights from the past and looking to the future.

Authors:  Bela Anand-Apte; Jennifer R Chao; Ruchira Singh; Heidi Stöhr
Journal:  J Neurosci Res       Date:  2018-08-21       Impact factor: 4.164

6.  Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer.

Authors:  Chandramu Chetty; Sajani S Lakka; Praveen Bhoopathi; Sateesh Kunigal; Roger Geiss; Jasti S Rao
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

7.  TIMP3 Modulates GHR Abundance and GH Sensitivity.

Authors:  Yue Zhang; Xiangdong Wang; Kimberly Loesch; Larry A May; George E Davis; Jing Jiang; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2016-04-13

8.  Cell surface-bound TIMP3 induces apoptosis in mesenchymal Cal78 cells through ligand-independent activation of death receptor signaling and blockade of survival pathways.

Authors:  Christina Koers-Wunrau; Corinna Wehmeyer; Anja Hillmann; Thomas Pap; Berno Dankbar
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.